HIGHLIGHTS
- who: ID and colleagues from the Bioinformatics Research Center, Cedars-Sinai Medical Center, California, USA have published the paper: Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?, in the Journal: (JOURNAL)
- what: The authors investigate these claims in the setting of continuous dose levels of the two agents. The authors compare trial safety and efficiency of the estimated maximum tolerated dose (MTD) curve between models that include an interaction term with models without the synergism parameter with extensive simulations. The authors show using simulation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.